Desvenlafaxine
Product Images NDC 68071-2704

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68071-2704). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2704 3)

Packaging label for Desvenlafaxine 50 mg extended-release tablets, bottle of 30, labeled by NuCare Pharmaceuticals, Inc. The label includes NDC 68071-2704-3, directions to see the manufacturer's label for full ingredients, a warning to keep out of reach of children, and storage instructions to keep at controlled temperature 68-77°F.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

A pharmacokinetic figure showing geometric mean ratios (with 90% confidence intervals) for Cmax and AUC of Desvenlafaxine across varying degrees of renal and hepatic impairment and different population groups by gender and age. The x-axis represents change relative to reference, ranging from 0.5 to 3.5.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

A pharmacokinetic chart showing the geometric mean ratio and 90% confidence interval of Cmax and AUC changes for Desvenlafaxine when administered with the CYP3A4 inhibitor Ketoconazole. The chart plots change relative to reference on a horizontal axis ranging from 0.5 to 2.0, with Cmax and AUC values and their confidence intervals indicated by markers and error bars.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

A forest plot showing geometric mean ratios (90% confidence intervals) for pharmacokinetic parameters (Cmax and AUC) assessing drug interactions between Desvenlafaxine at various doses and interacting drugs Desipramine, Midazolam, Tamoxifen, and Aripiprazole. The plot displays ratios relative to reference values, indicating changes in Cmax and AUC with confidence intervals for each interaction.*

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

A survival curve chart showing estimated proportion of patients with relapse (%) on the y-axis over time to relapse in days (up to 200 days) on the x-axis. The chart compares Desvenlafaxine Extended-Release Tablets 50 mg and placebo groups, illustrating differences in relapse rates over time.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

Kaplan-Meier curve chart showing the estimated proportion of patients with relapse over time (days from randomization) comparing Desvenlafaxine Extended-Release Tablets and placebo groups. The y-axis represents the percentage of patients with relapse, and the x-axis represents time in days up to approximately 180.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

Chemical structure diagram showing the molecular structure of desvenlafaxine, including functional groups such as hydroxyl, amine, and carboxyl groups, with associated molecular bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.